ThromboGenics : Regulated Information - Transparency Statement

Regulated Information - Transparency Statement

Leuven, Belgium, 26 April 2017 - Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 26 April 2017 from Mr Thomas M Clay and from Mr Landon T. Clay and controlled entities (East Hill Hedge Fund LLC, Monadnock Charitable Lead Annuity Trust, Clay Fellowships Charitable Trust and The Clay Mathematics Institute, Inc., or the 'East Hill Management Company LLC).

Thomas M. Clay notified that, on 24 April 2017, the ThromboGenics shares controlled by himself have increased to 2,790,494 shares, or 7.73% of the current 36,094,349 outstanding ThromboGenics shares.

Landon T. Clay notified that, on 24 April 2017, the ThromboGenics shares controlled by himself and entities under his control have decreased to 571,061 shares, or 1.58% of the current 36,094,349 outstanding ThromboGenics shares.

On 26 April 2017, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

For further information please contact:

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

In January 2017, ThromboGenics enrolled its first patient in a Phase II clinical study evaluating THR-317, a PIGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or as a combination therapy with anti-VEGF treatments.

In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA® (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics, Inc. in the US. Novartis commercializes JETREA® outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered 'forward-looking'. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws..